Topical Delivery of SiRNA to Psoriatic Skin Model Using High Molecular Weight Chitosan Derivatives: In Vitro and in Vivo Studies

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Date 2025 Feb 5

PMID 39907973

Authors

Andre Miguel Martinez Junior

Thalles Fernando Rocha Ruiz

Patricia Simone Leite Vilamaior

Vera Aparecida de Oliveira Tiera

Sebastiao Roberto Taboga

Marcio Jose Tiera

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a chronic inflammatory skin disease that, like other immune-mediated conditions, may benefit from small interfering RNA (siRNA)-based therapies, which are emerging as a promising alternative by addressing several limitations of current treatments. In this study, topical formulations of chitosan-based vectors were developed to deliver siRNA targeting tumor necrosis factor alpha (TNFα) to inflamed skin. Grafting diisopropylethylamine (DIPEA) and polyethylene glycol (PEG) onto the chitosan backbone enhanced siRNA delivery efficiency under physiological conditions, forming robust polymeric vectors with high structural and colloidal stability. These vectors provided siRNA protection against RNAse degradation and oxidative damage. Additionally, the chitosan derivatives displayed lysozyme-mediated biodegradability comparable to native chitosan, while PEG was released in response to reductive environments, supporting controlled vector disassembly. The PEGylated DIPEA-chitosan/siRNA polyplexes demonstrated positive zeta potentials (up to + 11 mV), particle sizes of 100-200 nm, and very low cytotoxicity in keratinocyte and fibroblast cell lines. In vitro, the polyplexes achieved TNFα knockdown levels (65%) in RAW macrophages, comparable to those obtained with Lipofectamine™. Topical formulations showed enhanced interaction of vectors with skin models (Strat-M and porcine ear skin) compared to naked siRNA. Furthermore, in vivo studies indicated that hair follicles were a key route for polyplexes to penetrate deeper skin layers. A rodent model of psoriasis induced by imiquimod was treated topically with these vectors, resulting in approximately a 50% reduction in TNFα levels at inflammation sites, decreased immune cell infiltration, and preservation of epidermal structure. These findings collectively underscore the potential of DIPEA-chitosan-based vectors for topical siRNA-based therapies.

References

Vicic M, Kastelan M, Brajac I, Sotosek V, Massari L . Current Concepts of Psoriasis Immunopathogenesis. Int J Mol Sci. 2021; 22(21). PMC: 8584028. DOI: 10.3390/ijms222111574. View

Raychaudhuri S, Maverakis E, Raychaudhuri S . Diagnosis and classification of psoriasis. Autoimmun Rev. 2014; 13(4-5):490-5. DOI: 10.1016/j.autrev.2014.01.008. View

Lee H, Kim M . Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci. 2023; 24(17). PMC: 10487560. DOI: 10.3390/ijms241713313. View

Viola R, Mastorino L, Megna M, Damiani G, Gisondi P, Argenziano G . Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort. Int J Dermatol. 2024; 63(3):351-358. DOI: 10.1111/ijd.17005. View

McLean R, Sima A, Beaty S, Jones E, Eckmann T, Low R . Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023; 13(11):2753-2768. PMC: 10613189. DOI: 10.1007/s13555-023-01028-5. View

Posner J, Barrington P, Brier T, Datta-Mannan A . Monoclonal Antibodies: Past, Present and Future. Handb Exp Pharmacol. 2019; 260:81-141. DOI: 10.1007/164_2019_323. View

Pandi P, Jain A, Raju S, Khan W . Therapeutic approaches for the delivery of TNF-α siRNA. Ther Deliv. 2017; 8(5):343-355. DOI: 10.4155/tde-2017-0011. View

Zhao F, Zhao J, Wei K, Jiang P, Shi Y, Chang C . Targeted siRNA Therapy for Psoriasis: Translating Preclinical Potential into Clinical Treatments. Immunotargets Ther. 2024; 13:259-271. PMC: 11104385. DOI: 10.2147/ITT.S458800. View

Suzuki I, de Araujo M, Bagnato V, Bentley M . TNFα siRNA delivery by nanoparticles and photochemical internalization for psoriasis topical therapy. J Control Release. 2021; 338:316-329. DOI: 10.1016/j.jconrel.2021.08.039. View

10.

Lee W, Chou W, Lin Z, Sung C, Lin C, Fang J . Laser-assisted nanocarrier delivery to achieve cutaneous siRNA targeting for attenuating psoriasiform dermatitis. J Control Release. 2022; 347:590-606. DOI: 10.1016/j.jconrel.2022.05.032. View

11.

Shtykalova S, Deviatkin D, Freund S, Egorova A, Kiselev A . Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications. Life (Basel). 2023; 13(4). PMC: 10142071. DOI: 10.3390/life13040903. View

12.

Dong L, Li Y, Cong H, Yu B, Shen Y . A review of chitosan in gene therapy: Developments and challenges. Carbohydr Polym. 2023; 324:121562. DOI: 10.1016/j.carbpol.2023.121562. View

13.

Cao Y, Tan Y, Wong Y, Jie Liew M, Venkatraman S . Recent Advances in Chitosan-Based Carriers for Gene Delivery. Mar Drugs. 2019; 17(6). PMC: 6627531. DOI: 10.3390/md17060381. View

14.

Martins G, Segalla Petronio M, Lima A, Martinez Junior A, Tiera V, Calmon M . Amphipathic chitosans improve the physicochemical properties of siRNA-chitosan nanoparticles at physiological conditions. Carbohydr Polym. 2019; 216:332-342. DOI: 10.1016/j.carbpol.2019.03.098. View

15.

Weecharangsan W, Opanasopit P, Ngawhirunpat T, Apirakaramwong A, Rojanarata T, Ruktanonchai U . Evaluation of chitosan salts as non-viral gene vectors in CHO-K1 cells. Int J Pharm. 2007; 348(1-2):161-8. DOI: 10.1016/j.ijpharm.2007.07.011. View

16.

He C, Yin L, Tang C, Yin C . Trimethyl chitosan-cysteine nanoparticles for systemic delivery of TNF-α siRNA via oral and intraperitoneal routes. Pharm Res. 2013; 30(10):2596-606. DOI: 10.1007/s11095-013-1086-4. View

17.

Bholakant R, Qian H, Zhang J, Huang X, Huang D, Feijen J . Recent Advances of Polycationic siRNA Vectors for Cancer Therapy. Biomacromolecules. 2020; 21(8):2966-2982. DOI: 10.1021/acs.biomac.0c00438. View

18.

Chen Q, Qi Y, Jiang Y, Quan W, Luo H, Wu K . Progress in Research of Chitosan Chemical Modification Technologies and Their Applications. Mar Drugs. 2022; 20(8). PMC: 9410415. DOI: 10.3390/md20080536. View

19.

Peng L, Wagner E . Polymeric Carriers for Nucleic Acid Delivery: Current Designs and Future Directions. Biomacromolecules. 2019; 20(10):3613-3626. DOI: 10.1021/acs.biomac.9b00999. View

20.

Chen J, Wang K, Wu J, Tian H, Chen X . Polycations for Gene Delivery: Dilemmas and Solutions. Bioconjug Chem. 2018; 30(2):338-349. DOI: 10.1021/acs.bioconjchem.8b00688. View